Pre-made Matuzumab benchmark antibody ( Whole mAb, anti-EGFR therapeutic antibody, Anti-ERBB/ERRP/HER1/mENA/ERBB1/PIG61/NISBD2 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Matuzumab biosimilar, Whole mAb, Anti-EGFR Antibody: Anti-ERBB/ERRP/HER1/mENA/ERBB1/PIG61/NISBD2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Matuzumab (formerly EMD 72000) is a humanized monoclonal antibody for the treatment of cancer. It binds to the epidermal growth factor receptor (EGFR) with high affinity. The mouse monoclonal antibody (mAb425) from which matuzumab was developed at the Wistar Institute in Philadelphia, Pennsylvania

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-337-1mg	1mg	3090
GMP-Bios-ab-337-10mg	10mg	Inquiry
GMP-Bios-ab-337-100mg	100mg	Inquiry
GMP-Bios-ab-337-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Matuzumab biosimilar, Whole mAb, Anti-EGFR Antibody: Anti-ERBB/ERRP/HER1/mENA/ERBB1/PIG61/NISBD2 therapeutic antibody
INN Name	Matuzumab
Target	EGFR
Format	Whole mAb
Derivation	Humanized
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	nd
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Discontinued
100% SI Structure	3c08:HL/5vr9:HL:AB
99% SI Structure	5vsi:HL/3c09:HL:CB
95-98% SI Structure	None
Year Proposed	2003
Year Recommended	2003
Companies	ImClone Systems;Merck KGaA;Takeda
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Cervical cancer;Colorectal cancer;Gastric cancer;Head and neck cancer;Non-small cell lung cancer;Ovarian cancer
Development Tech	na